¼¼°èÀÇ µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT) ½ÃÀå
Isothermal Nucleic Acid Amplification Technology (INAAT)
»óǰÄÚµå : 1545565
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 179 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,263,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,789,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT) ¼¼°è ½ÃÀåÀº 2030³â±îÁö 67¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 34¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT) ¼¼°è ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 10.3% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 67¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ INAAT ½Ã¾àÀº CAGR 10.1%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 46¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, INAAT ±â±â ºÎ¹®Àº ºÐ¼® ±â°£ µ¿¾È CAGR 10.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¹Ì±¹ ½ÃÀå 8¾ï 9,830¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.7%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT) ½ÃÀåÀº 2023³â 8¾ï 9,830¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 9.7%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 10¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 9.2%¿Í 8.6%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¾à 8.0%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT) ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT)ÀÌ ºÐÀÚÁø´Ü¿¡ Çõ¸íÀ» °¡Á®¿Ã ÀÌÀ¯´Â ¹«¾ùÀϱî?

µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT)Àº ¿­ »çÀÌŬ¸µÀÌ ÇÊ¿ä ¾ø´Â ½Å¼ÓÇÏ°í ¹Î°¨ÇÏ¸ç Æ¯ÀÌÀûÀÎ ÇÙ»ê °ËÃâ ¹æ¹ýÀ» Á¦°øÇÔÀ¸·Î½á ºÐÀÚÁø´Ü ºÐ¾ß¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ±âÁ¸ PCR ±â¼ú°ú ´Þ¸® INAAT´Â ÀÏÁ¤ÇÑ ¿Âµµ¿¡¼­ ÀÛµ¿Çϱ⠶§¹®¿¡ ÇÊ¿äÇÑ Àåºñ°¡ °£¼ÒÈ­µÇ°í °á°ú µµÃâ±îÁö °É¸®´Â ½Ã°£ÀÌ ´ÜÃàµË´Ï´Ù. ÀÌ ±â¼úÀº ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´ÜÀÌ ÇʼöÀûÀÎ ÇöÀå Áø·á ȯ°æ¿¡¼­ ƯÈ÷ À¯¿ëÇϸç, INAAT´Â °¨¿°¼º Áúȯ, À¯Àü¼º Áúȯ, ¾Ï ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâ¿¡ ³Î¸® »ç¿ëµÇ¾î Çö´ë ÀÇ·á¿¡ ÇʼöÀûÀÎ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ °í±Þ °Ë»ç ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖ´Â ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æ¿¡¼­ ÀÏ»óÀûÀÎ ÀÓ»ó Áø´Ü¿¡ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº INAATÀÇ ´É·ÂÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº INAATÀÇ ´É·ÂÀ» Å©°Ô Çâ»ó½ÃÄÑ ´õ¿í °ß°íÇϰí, ´ÙÀç´Ù´ÉÇϸç, »ç¿ëÇϱ⠽±°Ô ¸¸µé¾ú½À´Ï´Ù. È¿¼Ò ¼³°è ¹× ¹ÝÀÀ È­ÇÐÀÇ Çõ½ÅÀº INAAT ºÐ¼®ÀÇ ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó½ÃÄÑ º¹ÀâÇÑ »ý¹°ÇÐÀû ½Ã·á¿¡¼­ ³·Àº ¼öÁØÀÇ ÇÙ»êÀ» °ËÃâÇÒ ¼ö ÀÖ°Ô Çß½À´Ï´Ù. ¶ÇÇÑ, INAAT°¡ ³»ÀåµÈ ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿î ±â±âÀÇ °³¹ß·Î ÇöÀå Áø´Ü ¹× °¡Á¤ ³» °Ë»ç¿¡ ´ëÇÑ È°¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ½Å¼ÓÇÏ°í ºÐ»êµÈ °Ë»ç°¡ Áß¿äÇÑ ½ÅÁ¾ °¨¿°º´°úÀÇ ½Î¿ò¿¡¼­ ƯÈ÷ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¶ÇÇÑ, INAAT¿Í µðÁöÅÐ ±â¼ú ¹× µ¥ÀÌÅÍ ºÐ¼®ÀÇ ÅëÇÕÀº Áúº´ ¹ß»ýÀÇ ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ »õ·Î¿î °¡´É¼ºÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû °³¼±À¸·Î °øÁߺ¸°Ç¿¡¼­ °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ INAATÀÇ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

INAAT ½ÃÀå¿¡´Â ¾î¶² µµÀü°ú ±âȸ°¡ Á¸ÀçÇÒ±î?

INAATÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖÀ½¿¡µµ ºÒ±¸Çϰí, INAAT ½ÃÀåÀº Ç¥ÁØÈ­ÀÇ Çʿ伺, ±ÔÁ¦ À庮, ±âÁ¸ ºÐÀÚÁø´Ü ±â¼ú°úÀÇ °æÀï µî ¿©·¯ °¡Áö µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¼­·Î ´Ù¸¥ INAAT Ç÷§Æû °£¿¡ Ç¥ÁØÈ­µÈ ÇÁ·ÎÅäÄݰú ½Ã¾àÀÌ ¾ø±â ¶§¹®¿¡ °á°úÀÇ ÆíÂ÷°¡ ¹ß»ýÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ÀÓ»ó Àû¿ë¿¡ ÀÖ¾î ¿ì·ÁµÇ´Â ºÎºÐÀÔ´Ï´Ù. ¶ÇÇÑ, Áø´Ü °Ë»ç¿¡ ´ëÇÑ ±î´Ù·Î¿î ±ÔÁ¦ ¿ä°ÇÀº ƯÈ÷ ¹Ì±¹À̳ª À¯·´°ú °°ÀÌ ±ÔÁ¦°¡ ¾ö°ÝÇÑ ½ÃÀå¿¡¼­´Â INAAT ½ÅÁ¦Ç°ÀÇ »ó¿ëÈ­¸¦ Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ µµÀüÀº ±â¼ú Çõ½Å°ú ½ÃÀå ¼ºÀåÀÇ ±âȸ°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. Ç¥ÁØÈ­µÇ°í »ç¿ëÇϱ⠽¬¿î INAAT ŰƮ¸¦ °³¹ßÇÏ¿© ±¤¹üÀ§ÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹ÞÀ» ¼ö ÀÖ´Â ±â¾÷µéÀº ºü¸¥ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ, °¨¿°º´ ´ëÀÀ, ¾Ï °ËÁø, °³ÀÎ ¸ÂÃãÇü ÀÇ·á µîÀÇ ºÐ¾ß¿¡¼­ Áø´Ü µµ±¸ °³¼±¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿ä±¸°¡ INAAT¿¡ ´ëÇÑ °ü½É°ú ÅõÀÚ¸¦ Áö¼ÓÀûÀ¸·Î ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

INAAT ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

µî¿Â ÇÙ»ê ÁõÆø ±â¼ú(INAAT) ½ÃÀåÀÇ ¼ºÀåÀº ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Àü¿°º´ À¯Çà, ºÐÀÚ»ý¹°ÇÐÀÇ ¹ßÀü µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ COVID-19 ÆÒµ¥¹Í°ú °°Àº ¼¼°è º¸°Ç À§±â »óȲ¿¡¼­ ÇöÀå °Ë»çÀÇ Çʿ伺ÀÌ Áõ°¡Çϸ鼭 ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸ÀÇ Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â INAATÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¾¾çÇÐ, À¯ÀüÀÚ °Ë»ç µî INAATÀÇ ¿ëµµ°¡ °¨¿°¼º Áúȯ °Ë»ç ¿Ü¿¡µµ È®´ëµÇ°í ÀÖ´Â Á¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, INAAT Ç÷§ÆûÀÇ ¼º´É°ú »ç¿ë ÆíÀǼºÀ» Çâ»ó½ÃŰ´Â ±â¼ú ¹ßÀüÀº ÀÓ»ó ½ÇÇè½Ç¿¡¼­ ¿ø°ÝÁö±îÁö ´Ù¾çÇÑ È¯°æ¿¡¼­ Æø³Ð°Ô äÅÃµÉ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ Á¶±â Áø´Ü°ú ¸ÂÃã Ä¡·áÀÇ Á߿伺À» °è¼Ó °­Á¶ÇÔ¿¡ µû¶ó INAAT¿¡ ´ëÇÑ ¼ö¿ä´Â ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â Ãß°¡ÀûÀÎ ¹ßÀü°ú ½ÃÀå È®ÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÁÖ¸ñÇÒ ¸¸ÇÑ 12°³ ±â¾÷)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market to Reach US$6.7 Billion by 2030

The global market for Isothermal Nucleic Acid Amplification Technology (INAAT) estimated at US$3.4 Billion in the year 2023, is expected to reach US$6.7 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2023-2030. INAAT Reagents, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the INAAT Instruments segment is estimated at 10.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$898.3 Million While China is Forecast to Grow at 9.7% CAGR

The Isothermal Nucleic Acid Amplification Technology (INAAT) market in the U.S. is estimated at US$898.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 9.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Key Trends & Drivers Summarized

Why Is Isothermal Nucleic Acid Amplification Technology (INAAT) Revolutionizing Molecular Diagnostics?

Isothermal Nucleic Acid Amplification Technology (INAAT) is revolutionizing the field of molecular diagnostics by providing a rapid, sensitive, and specific method for detecting nucleic acids without the need for thermal cycling. Unlike traditional PCR techniques, INAAT operates at a constant temperature, simplifying the equipment required and reducing the time to results. This technology is particularly valuable in point-of-care settings, where quick and accurate diagnostics are essential. INAAT is being widely adopted for the detection of infectious diseases, genetic disorders, and cancer biomarkers, making it an indispensable tool in modern healthcare. The technology's ability to deliver results quickly and with high accuracy is driving its integration into routine clinical diagnostics, especially in resource-limited settings where access to sophisticated laboratory infrastructure is limited.

How Are Technological Advancements Enhancing the Capabilities of INAAT?

Technological advancements are significantly enhancing the capabilities of INAAT, making it more robust, versatile, and accessible. Innovations in enzyme design and reaction chemistry are improving the sensitivity and specificity of INAAT assays, enabling the detection of low levels of nucleic acids in complex biological samples. Additionally, the development of portable and user-friendly devices that incorporate INAAT is expanding its use in field diagnostics and at-home testing. These advancements are particularly impactful in the fight against emerging infectious diseases, where rapid and decentralized testing is critical. The integration of INAAT with digital technologies and data analytics is also opening new possibilities for real-time monitoring of disease outbreaks and personalized medicine. These technological improvements are driving the adoption of INAAT across various sectors, from public health to personalized medicine.

What Challenges and Opportunities Exist in the INAAT Market?

Despite its growing adoption, the INAAT market faces several challenges, including the need for greater standardization, regulatory hurdles, and competition from established molecular diagnostics technologies. The lack of standardized protocols and reagents across different INAAT platforms can lead to variability in results, which is a concern for clinical applications. Additionally, the stringent regulatory requirements for diagnostic tests can slow down the commercialization of new INAAT products, particularly in highly regulated markets like the United States and Europe. However, these challenges also present opportunities for innovation and market growth. Companies that can develop standardized, easy-to-use INAAT kits with broad regulatory approval will be well-positioned to capitalize on the growing demand for rapid diagnostics. Moreover, the ongoing need for improved diagnostic tools in areas such as infectious disease control, cancer screening, and personalized medicine continues to drive interest and investment in INAAT.

What Factors Are Driving Growth in the INAAT Market?

The growth in the Isothermal Nucleic Acid Amplification Technology (INAAT) market is driven by several factors, including the increasing demand for rapid and accurate diagnostics, the rising prevalence of infectious diseases, and advancements in molecular biology. The ongoing need for point-of-care testing, particularly in the context of global health crises like the COVID-19 pandemic, has highlighted the importance of quick and reliable diagnostic tools, boosting the adoption of INAAT. Additionally, the expansion of INAAT applications beyond infectious disease testing, such as in oncology and genetic testing, is contributing to market growth. Technological advancements that improve the performance and ease of use of INAAT platforms are also playing a crucial role, as they enable wider adoption across different settings, from clinical laboratories to remote locations. As healthcare systems continue to emphasize the importance of early diagnosis and personalized treatment, the demand for INAAT is expected to grow, driving further advancements and market expansion.

Select Competitors (Total 12 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â